482311-23-9Relevant articles and documents
BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS
-
Paragraph 0501-0502, (2021/11/13)
The disclosure is directed to, in part, to BCL-2 inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
FUSED BICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
-
Paragraph 00176; 00260, (2019/03/05)
Fused bicyclic compounds and uses thereof in medicine. In particular, provided are fused bicyclic compounds used as ASK1 active regulator and and use of the compounds in the manufacture of a drug for treating a disease regulated by ASK1. Further provided are a pharmaceutical composition and a method of treating a disease regulated by ASK1 comprising administering the compounds or pharmaceutical composition thereof.
PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH
-
Page/Page column 32; 48, (2018/08/12)
The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.
BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS
-
Page/Page column 70, (2010/09/17)
The present invention provides novel benzamide derivatives of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, W, Y, Z, R8, and R9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.